Life 2.0: The Promise and Challenge of a CRISPR Path to a Sustainable Planet
Organized by Barbara Meyer, Fyodor Urnov and Dana Carroll
Fully realizing the tremendous potential of gene editing will require such an interdisciplinary approach. The purpose of this colloquium is to enable a solution-oriented multidisciplinary dialog to address the following pressing questions: given the remarkable rate of progress in gene editing, what are the areas of its potential biggest impact on the planet in the next decade? what are the key obstacles – scientific, societal, economic – to that impact, in the Western world and in the developing world? The colloquium will thus gather leading experts, such as yourself, in various translational and societal aspects of gene editing (clinical; plant and animal agriculture); each session will conclude with a panel discussion aimed to identify, for a given real-world outcome, the key “pinch points” (scientific, economic, societal, political) on its path to the world.
Videos
- A limited number of videos are available for public viewing. More videos may be added as permission is received.
Agenda
Tuesday, December 10, 2019
Welcome Remarks, Barbara Meyer, University of California, Berkeley
Keynote lecture, A View From the Edge, Dana Carroll, University of Utah and Innovative Genomics Institute
Session 1: The translational promise of CRISPR and the urgency of the challenge
Functional single-cell genomics of human cytomegalovirus infection, Jonathan Weissman, University of California, San Francisco
Taming the Wild through Genome Editing of Model and Non-Model Organisms, Barbara Meyer, University of California, Berkeley
How gene therapy can address the public health challenge of genetic disease, Michele Calos, Stanford University
Serving up Science: The Future of Food, Pamela Ronald, University of California, Davis
The return of global infections in an age of war, political collapse, antiscience, and climate change, Peter Hotez, Baylor College of Medicine
Session 2: Societal considerations and challenges
CRISPR and the meaning of solidarity in a Balkanized world, Debra Mathews, Johns Hopkins University School of Medicine
The voice of many: Collective oversight of environmental gene editing, Natalie Kofler, Yale University
Going from the clinic to the world, Dan Wattendorf, Gates Foundation
Connecting on CRISPR: Effective public communication about genome editing and its applications, Dietram Scheufele, Wisconsin University
Panel discussion: Fyodor Urnov, moderator
Session 3: Genome editing for animal engineering
Editing Farmed Animals, Bruce Whitelaw, Roslin Institute
Transform Xenotransplantation using CRISPR-Cas, Luhan Yang, Qihan Biotech
FDA’s Science- and Risk-Based Framework and Genome Editing in Animals, Heather Lombardi, U.S. Food and Drug Administration
Panel discussion: Dana Carroll, moderator
Distinctive Voices Lecture
Introduction by Barbara Meyer
Genome Editing with CRISPR-Cas systems: Challenges and Opportunities in a New Era of Biology, Jennifer Doudna, University of California, Berkeley
Wednesday, December 11, 2019
Session 4: Genome editing for crop engineering
Invigorating plant breeding with genome editing, Zach Lippman, Cold Spring Harbor Laboratory
Overcoming Bottlenecks in Plant Gene Editing, Daniel Voytas, University of Minnesota
USDA Approach to Regulating Plant Breeding Innovation, Neil Hoffman, USDA
Panel discussion: Barbara Meyer, moderator
Session 5: Gene drives
Exploiting CRISPR technology to develop population suppression gene drive solutions for vector borne diseases, Andrea Crisanti, Imperial College London
The next generation of gene drives, Bruce Hay, California Institute of Technology
Synthetic threads through the web of life, Mary Power, University of California, Berkeley
Panel discussion: Heather Lombardi, moderator
Session 6: Genome editing for disease
CRISPR Correction of Muscle Disease, Eric Olson, University of Texas Southwestern
The next generation of edited humans, Fyodor Urnov, Innovative Genomics Institute
The Regulatory Landscape for Genome Editing, Peter Marks, Food and Drug Administration Center for Biologics Evaluation and Research
Panel discussion: Dana Carroll, moderator
Session 7: Editing the human germline
Genome editing in human embryos, Kathy Niakan, Francis Crick Institute
Medical indications for future germline editing, Shruthi Mahalingaiah, Harvard University
Ethical and Social Issues in Human Germline Editing, John H. Evans, University of California, San Diego
Panel discussion: Fyodor Urnov, moderator
The National Academy of Sciences gratefully acknowledges the generous support for this colloquium from the following organizations:
Innovative Genomics Institute.
